课题基金 / 基金详情

MECHANISM OF HUMAN B CELL SELECTION AND V GENE DIVERSIFICATION

MECHANISM OF HUMAN B CELL SELECTION AND V GENE DIVERSIFICATION
人类 B 细胞选择和 V 基因多样化的机制
批准号:
5206523
负责人:
JONATHAN BRAUN
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

JONATHAN BRAUN的其他基金

相似基金

相关文献

中文摘要
翻译
V基因超突变的抗原选择及相关过程 对抗体库有重大影响。 这些过程起作用 在B细胞发育的一个阶段, 人类淋巴瘤 该项目的特点是相应的 使用两个独特的实验系统的细胞和分子过程 在上一个补助期内开发的。 发现一种病毒抗原HIV gp 120可以选择性地结合并激活 通过VH 3表达的保守序列的大B细胞亚群 IG基因家族,通过与新的非CDR框架的明显相互作用 网站. 在临床HIV感染期间,VH 3 B细胞群是 最初扩增和激活,随后选择性克隆缺失 与CD 4 T细胞的损失平行。 这些发现可以 概念化为B细胞谱系的超抗原的先例。 这一概念的推论是,gp 120的生物干扰- 结合B细胞克隆可能是体液免疫的重要因素, 功能障碍和B细胞淋巴瘤发生的风险增加, 个体 在建议的项目中,我们将首先界定 gp 120-VH 3 IG相互作用的结构基础。 抗体基序 将定义结合所需的gp 120表位,并选择性地 将产生这种相互作用的肽或蛋白质拮抗剂。 其次,我们将确定艾滋病毒的细胞生物学过程- 诱导VH 3 B细胞耗竭。 我们将定义他们的直接反应, gp 120,以及候选VH 3耗竭机制的有效性。 第三,我们将评估这种超抗原的潜在作用 艾滋病毒相关性淋巴瘤发生的相互作用, HIV相关淋巴瘤与散发性淋巴瘤中VH 3 IG亚群的差异。 基于以下方法,开发了一种用于V基因超突变的实时检测方法: 检测突变活性的基因特异性PCR DNA修复试验 在原代B细胞或细胞系的内源性IG VDJ区段中。 我们 研究反映了基因转换过程的优势, 对于VDJ以序列和阶段特定的方式选择性地激活 超突变阳性(生发中心)B细胞中的节段。 在 建议的工作,我们的第一个目标是确定的结构特征, 这些事件通过基因组分离和基因的表征 转换轨迹和候选供体基因。 第二,原电池 将用酶特异性抑制剂和一组 免疫刺激寻找主要生化和细胞 这可能激活或沉默V基因转换的生理过程。 第三,超突变试验将用于筛选和表征 具有组成型或诱导型超突变的生发中心B细胞系 活动
英文摘要
Antigenic selection and the associated process of V gene hypermutation have a major influence on the antibody repertoire. These processes act at a stage in B-cell development also critical for the most common forms of human lymphomas. This project characterizes the corresponding cellular and molecular processes using two unique experimental systems developed in the previous grant period. A viral antigen, HIV gp120, was found to selectively bind and activate a large B-cell subset through conserved sequences expressed by the VH3 Ig gene family, through apparent interaction with novel non-CDR framework sites. During clinical HIV infection, the VH3 B-cell population is initially expanded and activated, followed by a selective clonal deletion paralleling the loss of CD4 T cells. These findings can be conceptualized as a precedent for superantigens of the B-cell lineage. The corollary of this concept is that the biologic disturbance of gp120- binding B-cell clones may be an important factor in the humoral immune dysfunction and elevated risk of B-cell lymphomagenesis in these individuals. In the proposed project, we will first define the structural basis of the gp120-VH3 Ig interaction. The antibody motifs and gp120 epitopes required for binding will be defined, and selective peptide or protein antagonists of this interaction will be generated. Second, we will determine the cell biologic processes accounting for HIV- induced VH3 B-cell depletion. We will define their direct response to gp120, and the effectiveness of candidate VH3 depletion mechanisms. Third, we will evaluate the potential role of this superantigen interaction in HIV-associated lymphomagenesis by testing the prevalence of this VH3 Ig subset among HIV-associated versus sporadic lymphomas. A real-time assay for V gene hypermutation has been developed, based on a gene-specific PCR DNA repair assay which detects mutational activity in endogenous Ig VDJ segments of primary B-cells or cell lines. Our studies reflect the predominance of a gene conversion process which is selectively active in a sequence and stage-specific manner for VDJ segments in hypermutation-positive (germinal center) B cells. In the proposed work, our first goal is to ascertain the structural features of these events by genomic isolation and characterization of the gene conversion tracks and candidate donor genes. Second, the primary cell assay will be manipulated with enzyme specific inhibitors and a panel of immunologic stimuli to search for predominant biochemical and cell physiologic processes which may activate or silence V gene conversion. Third, the hypermutation assay will be used to screen and characterize germinal center B-cell lines with constitutive or inducible hypermutation activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarking IBD patient-specific disease features using the epithelial antigenic peptidome
  • 批准号:
    10261547
  • 项目类别:
  • 资助金额:
    $20.88万
  • 财政年份:
    2020
  • 负责人:
    JONATHAN BRAUN
  • 依托单位:
Mechanisms of Intestinal Inflammation - Associated Systemic Genotoxicity
Tumor Immunology
B CELL IMMUNOREGULATION IN CROHN'S DISEASE
  • 批准号:
    7487327
  • 项目类别:
  • 资助金额:
    $22.23万
  • 财政年份:
    2007
  • 负责人:
    JONATHAN BRAUN
  • 依托单位:
海外基金